Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1986 1
1988 3
1989 5
1990 8
1991 1
1992 1
1993 4
1994 4
1995 5
1996 2
1997 4
1998 1
1999 8
2000 5
2001 6
2002 8
2003 6
2004 8
2005 10
2006 16
2007 15
2008 12
2009 8
2010 9
2011 10
2012 6
2013 1
2014 1
2015 5
2017 1
2018 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

172 results

Results by year

Filters applied: . Clear all
Page 1
Preoperative chemoradiotherapy for esophageal or junctional cancer.
van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; CROSS Group. van Hagen P, et al. Among authors: van dekken h. N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088. N Engl J Med. 2012. PMID: 22646630 Free article. Clinical Trial.
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A; CROSS study group. Shapiro J, et al. Among authors: van dekken h. Lancet Oncol. 2015 Sep;16(9):1090-1098. doi: 10.1016/S1470-2045(15)00040-6. Epub 2015 Aug 5. Lancet Oncol. 2015. PMID: 26254683 Clinical Trial.
The molecular biology of esophageal adenocarcinoma.
Koppert LB, Wijnhoven BP, van Dekken H, Tilanus HW, Dinjens WN. Koppert LB, et al. Among authors: van dekken h. J Surg Oncol. 2005 Dec 1;92(3):169-90. doi: 10.1002/jso.20359. J Surg Oncol. 2005. PMID: 16299787 Review.
Report of an Amsterdam working group on Barrett esophagus.
Offerhaus GJ, Correa P, van Eeden S, Geboes K, Drillenburg P, Vieth M, van Velthuysen ML, Watanabe H, Sipponen P, ten Kate FJ, Bosman FT, Bosma A, Ristimaki A, van Dekken H, Riddell R, Tytgat GN. Offerhaus GJ, et al. Among authors: van dekken h. Virchows Arch. 2003 Nov;443(5):602-8. doi: 10.1007/s00428-003-0906-z. Epub 2003 Sep 27. Virchows Arch. 2003. PMID: 14517678 Review. No abstract available.
Angiogenesis: a prognostic determinant in pancreatic cancer?
van der Zee JA, van Eijck CH, Hop WC, van Dekken H, Dicheva BM, Seynhaeve AL, Koning GA, Eggermont AM, ten Hagen TL. van der Zee JA, et al. Among authors: van dekken h. Eur J Cancer. 2011 Nov;47(17):2576-84. doi: 10.1016/j.ejca.2011.08.016. Epub 2011 Sep 28. Eur J Cancer. 2011. PMID: 21958461
172 results